Stock A271980 JEIL PHARMACEUTICAL CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Jeil Pharmaceutical Co.,Ltd

Equities

A271980

KR7271980005

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 28/05/2024 am IST 		5-day change 1st Jan Change
16,640 KRW +1.09% Intraday chart for Jeil Pharmaceutical Co.,Ltd -1.42% -2.69%
16/05 Jeil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Jeil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Jeil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Jeil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on December 10, 2020.
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback announced on December 10, 2020, has expired with 42,941 shares, representing 0.29% for KRW 1,521.88 million.
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan Extended till December 9, 2022.
CI
Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan Extended till June 9, 2022.
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback announced on December 10, 2020, has expired.
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan Extended till December 09, 2021.
CI
Rockwell Medical, Inc. Announces Submission of Triferic® New Drug Application in South Korea by Partner, Jeil Pharmaceutical Co., Ltd
CI
Jeil Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 3,000 million worth of its shares.
CI
Jeil Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
CI
Tranche Update on Jeil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on May 16, 2019.
CI
Jeil Pharmaceutical Co.,Ltd's Equity Buyback announced on May 16, 2019, has expired with 84,920 shares, representing 0.58% for KRW 2,707.67 million.
CI
Jeil Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 3,000 million worth of its shares.
CI
Jeil Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A271980 Stock
  4. News Jeil Pharmaceutical Co.,Ltd
  5. Highlights